MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
14.49
-0.03
-0.21%
Closed 16:01 11/04 EST
OPEN
14.52
PREV CLOSE
14.52
HIGH
15.25
LOW
14.18
VOLUME
506.65K
TURNOVER
0
52 WEEK HIGH
19.62
52 WEEK LOW
10.22
MARKET CAP
881.01M
P/E (TTM)
-4.6948
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLRX last week (1028-1101)?
Weekly Report · 1d ago
Weekly Report: what happened at PLRX last week (1021-1025)?
Weekly Report · 10/28 09:03
Weekly Report: what happened at PLRX last week (1014-1018)?
Weekly Report · 10/21 09:03
Pliant Therapeutics highlights INTEGRIS-PSC Phase 2a data on bexotegrast
TipRanks · 10/17 12:10
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast In Primary Sclerosing Cholangitis To Be Highlighted In A Late-Breaking Presentation At The Liver Meeting 2024
Benzinga · 10/17 12:01
Weekly Report: what happened at PLRX last week (1007-1011)?
Weekly Report · 10/14 09:03
Weekly Report: what happened at PLRX last week (0930-1004)?
Weekly Report · 10/07 09:03
PLIANT THERAPEUTICS APPOINTS GARY PALMER, M.D. AS SENIOR VICE PRESIDENT OF MEDICAL AFFAIRS
Reuters · 10/01 20:35
More
About PLRX
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.